Roivan­t's da­ta spin­out merges with ri­val in $7B deal

Last year
Deals

Po­laris, Ab­b­Vie, Bay­er back Stu­art Schreiber's hunt to turn can­cer treat­ments in­to cures

Last year
Financing
Startups

US to shell out $1.2B for sup­plies of Mer­ck­'s po­ten­tial Covid-19 an­tivi­ral

Last year
R&D
Coronavirus

On a con­tin­ued hunt for Parkin­son's break­throughs, Ab­b­Vie turns to a biotech in its port­fo­lio

Last year
Deals

An­a­lysts hound Bio­gen with ques­tions over Aduhelm's $56K price point as news of Alzheimer's OK rip­ples through glob­al mar­kets

Last year
Pharma

FDA re­jects Google's push to add vir­tu­al ex­am for Parkin­son’s dis­ease to its smart­watch

Last year
Pharma
FDA+

End­points News poll: Let's get your opin­ion on that con­tro­ver­sial ad­u­canum­ab ap­proval

Last year
Pharma

Trail­ing the Big Phar­ma play­ers, a less­er known BC­MA CAR-T can­di­date comes in­to the spot­light

Last year
R&D
China

Just how sad­ly mis­guid­ed is the FDA on ad­u­canum­ab?

Last year
Bioregnum

Opin­ion: How the FDA bent its rules for Bio­gen’s Alzheimer’s drug and why that’s bad for the en­tire bio­phar­ma in­dus­try

Last year
FDA+
Opinion

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

Last year
R&D
Pharma

No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

Last year
FDA+

J&J breaks off al­liance with ar­genx, drop­ping CD70 AML drug and ax­ing $1.3B in biobucks

Last year
Deals

Glax­o­SmithK­line, As­traZeneca butt heads over li­cens­ing rights to key PARP in­hibitor — re­port

Last year
Pharma

What ad­u­canum­ab means for Alzheimer's, un­pack­ing a safe­ty bar­ri­er in CAR-T, the push to up­grade a key ALS tri­al tool, and more

Last year
Weekly

What­ev­er the FDA de­cides on ad­u­canum­ab, Alzheimer's re­search is fi­nal­ly, most­ly, kind of mov­ing be­yond the amy­loid hy­poth­e­sis

Last year
R&D
In Focus

Eliz­a­beth War­ren wants Gilead CEO Daniel O'­Day in the hot seat to talk drug pric­ing and com­pet­i­tive­ness

Last year
People
Coronavirus

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is still the way to go

Last year
R&D
Cell/Gene Tx

Bris­tol My­ers sued over $6B Cel­gene CVR as trustee claims 'bla­tant mis­con­duc­t' for liso-cel de­lays

Last year
Pharma

#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

Last year
R&D

#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

Last year
R&D

#AS­CO21: Bris­tol My­er­s' so­lo, dual I/O reg­i­mens best chemo alone — with one ex­cep­tion — in first-line esophageal pa­tients

Last year
R&D

#AS­CO21: As­traZeneca's Lyn­parza earns win in ear­ly breast can­cer pa­tients, crack­ing open post-surgery po­ten­tial

Last year
R&D
Pharma

#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

Last year
R&D
First page Previous page 117118119120121122123 Next page Last page